Innate Pharma SA Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Sep 12, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
TL;DR
Innate Pharma SA filed a routine 6-K, no major news here.
AI Summary
On September 12, 2024, Innate Pharma SA filed a Form 6-K. This report is for a foreign private issuer and does not contain specific financial figures or operational updates beyond confirming its filing status. The company is based in Marseille, France, and operates in the biological products sector.
Why It Matters
This filing indicates Innate Pharma SA is meeting its reporting obligations as a foreign private issuer with the SEC, which is standard procedure for companies with U.S. listings.
Risk Assessment
Risk Level: low — This filing is a standard procedural report and does not contain new material information that would typically impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 0001598599-24-000069 (document_id) — Accession Number
- September 12, 2024 (date) — Filing Date
- Marseille, France (location) — Company Headquarters
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
What is the filing date of this report?
The report was filed on September 12, 2024.
Where is Innate Pharma SA headquartered?
Innate Pharma SA is headquartered at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma SA file annual reports under Form 20-F?
Yes, the filing indicates that Innate Pharma SA files annual reports under cover of Form 20-F.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-09-12 06:15:07
Filing Documents
- a6k-iphx240912.htm (6-K) — 9KB
- exhibit991-240912.htm (EX-99.1) — 191KB
- 0001598599-24-000069.txt ( ) — 201KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 12, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer